Prometheus Biosciences to Participate at the Cowen 42nd Annual Healthcare Conference
March 01 2022 - 08:30AM
Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage
biotechnology company pioneering a precision medicine approach for
the discovery, development, and commercialization of novel
therapeutic and companion diagnostic products for the treatment of
immune-mediated diseases, today announced that Mark McKenna,
Chairman and CEO along with members of management, will conduct a
virtual fireside chat at the Cowen 42nd Annual Healthcare
Conference on March 7, 2022 at 12:50 PM ET.
A live and archived webcast of the virtual
fireside chat will be available via the Events & Webcasts page
on the Investor section of the Prometheus Biosciences website.
About Prometheus
Biosciences
Prometheus Biosciences, Inc. is a clinical-stage biotechnology
company pioneering a precision medicine approach for the discovery,
development, and commercialization of novel therapeutic and
companion diagnostic products for the treatment of immune-mediated
diseases. The Company’s precision medicine platform,
Prometheus360TM, combines proprietary machine learning-based
analytical approaches with one of the world’s largest
gastrointestinal bioinformatics databases to identify novel
therapeutic targets and develop therapeutic candidates to engage
those targets.
The Company’s lead candidate, PRA023, is an IgG1 humanized
monoclonal antibody (mAb) for the treatment of immune-mediated
diseases including Ulcerative colitis (UC), Crohn’s disease (CD),
and the newly identified systemic sclerosis-associated interstitial
lung disease (SSc-ILD). The Company is currently conducting a Phase
2 trial in UC patients and a Phase 2a trial in CD patients, each
utilizing a proprietary genetic-based companion diagnostic designed
to identify patients who are predisposed to increased expression of
TL1A and therefore potentially more likely to respond to PRA023.
The company also plans to initiate a Phase 2 clinical trial for
PRA023 in SSc-ILD in the first quarter of 2022.
Prometheus Biosciences Contact:Noel KurdiVP
Investor Relations and Communications(646)
241-4400nkurdi@prometheusbiosciences.com
Media contact:Juniper PointAmy Conrad(858)
914-1962media@prometheusbiosciences.com
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Mar 2023 to Mar 2024